The angiopietin-1–Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice
Lakshmi Kugathasan, Julie Basu Ray, Yupu Deng, Effat Rezaei, Daniel J. Dumont, and Duncan J. Stewart

The authors regret that in Figure 1 of their article panels A and B were mislabeled. The html and pdf versions of this article have been corrected. The corrected figure appears below:
The angioptien-1–Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice

Lakshmi Kugathasan, Julie Basu Ray, Yupu Deng, Effat Rezaei, Daniel J. Dumont, and Duncan J. Stewart

The role of the angiopietin-1 (Ang1)–Tie2 pathway in the pathogenesis of pulmonary arterial hypertension (PAH) is controversial. Although Ang1 is well known to prevent endothelial activation and injury in systemic vascular beds, this pathway has been suggested to mediate pulmonary vascular remodeling in PAH. Therefore, we used transgenic models to determine the effect of increased or decreased Tie2 activity on the development of PAH.

We now report modest spontaneous elevation in right ventricular systolic pressure in Tie2-deficient mice (Tie2+/−) compared with wild-type (WT) littermate controls, which was exacerbated upon chronic exposure to the clinically relevant PAH triggers, serotonin (5-HT) or interleukin-6 (IL-6). Moreover, overexpression of Ang1 in transgenic mice had no deleterious effect on pulmonary hemodynamics and, if anything, blunted the response to 5-HT.

Exposure to 5-HT or IL-6 also decreased lung Ang1 expression, further reducing Tie2 activity and inducing pulmonary apoptosis in the Tie2+/− group only. Similarly, cultured pulmonary artery endothelial cells subjected to Tie2 silencing demonstrated increased susceptibility to apoptosis after 5-HT treatment. Finally, treatment of Tie2-deficient mice with Z-VAD, a pan-caspase inhibitor, prevented the pulmonary hypertensive response to 5-HT. Thus, these findings firmly establish that endothelial survival signaling via the Ang1–Tie2 pathway is protective in PAH.

Abbreviations used: 5-HT, serotonin; Ang, angiopoietin; BT, binary transgenic; EC, endothelial cell; eNOS, endothelial NO synthase; NBT, non-BT, PAH, pulmonary arterial hypertension; PI, propidium iodide; R.V, right ventricle; RVSP, right ventricular systolic pressure; SBP, systolic blood pressure; sIL-6R, soluble IL-6R; SMC, smooth muscle cell; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling.

© 2009 Kugathasan et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/.
1997) but is now recognized to have context-dependent agonistic properties, and has been reported to activate the Tie2 receptor at high concentration (Kim et al., 2000) or during prolonged incubation (Teichert-Kulisiewska et al., 2001).

Despite considerable evidence supporting a protective action for the Ang1–Tie2 pathway in systemic blood vessels (Chen and Stinnett, 2008; Lai et al., 2008; Lee et al., 2008), the role of this system in the pulmonary microvasculature, particularly in PAH, remains highly controversial. Thistlethwaite et al. reported remarkable increases in Ang1 expression and Tie2 activity in the lungs of PAH patients compared with control lung samples, in which both were nearly undetectable (Thistlethwaite et al., 2001; Du et al., 2003). However, other groups have found high basal levels of Ang1 expression and Tie2 activity in the normal human lung (Kugathasan et al., 2005; Eddahibi et al., 2006); indeed, the lung has been reported to exhibit the highest levels of Ang1–Tie2 expression and activity of all organs (Wong et al., 1997; Witzenbichler et al., 1998). Nonetheless, the Thistlethwaite group has also reported that overexpression of Ang1 by means of transfection with adenoviral (Sullivan et al., 2003) or adeno-associated viral vectors (Chu et al., 2004) produced PAH in rats. Again, these findings are in conflict with other reports demonstrating that nonviral Ang1 gene transfer reduced right ventricular systolic pressure (RVSP) and vascular remodeling in both the monocrotaline (Zhao et al., 2003) and chronic hypoxia (Kugathasan et al., 2005) models of PAH, even improving survival in the former. These discrepancies may be related to confounding influences of viral vectors that were used for transfection, because these may have proinflammatory effects, or surgical manipulation, in particular the clamping of delicate pulmonary veins that was performed to enhance pulmonary gene transfer (Sullivan et al., 2003; Chu et al., 2004).

Therefore, in the present study we relied on transgenic approaches to study the effects of both loss or gain of function of the Ang1–Tie2 pathway on pulmonary hemodynamics and remodeling. We now report that Tie2 heterozygous deficient mice showed mild spontaneous increases in RVSP and an exaggerated pulmonary hypertensive response to chronic exposure to serotonin (5-HT) or IL-6. This was associated with decreased lung Ang1 levels and Tie2 receptor activation, and increased peripheral lung apoptosis in Tie2-deficient mice only. Moreover, the inhibition of apoptosis with a pan-caspase inhibitor, Z-VAD, prevented PAH in response to 5-HT in Tie2+/− animals, whereas overexpression of Ang1 using a conditional transgenic model did not result in PAH and, if anything, blunted the pulmonary hypertensive response to 5-HT exposure. Therefore, the evidence from these transgenic models supports the view that the Ang1–Tie2 pathway acts to protect against the development of PAH, largely by preventing apoptosis and early lung microvascular loss.

RESULTS

Phenotypic characterization of WT and Tie2+/− mice
Western blot analysis of lung Tie2 and endothelial NO synthase (eNOS) protein revealed a reduction of ~50% in expression levels in Tie2+/− compared with WT mice (P < 0.01 and 0.05, respectively; Fig. 1, A and B). Interestingly, basal protein levels of Ang1 in the lung were slightly increased in Tie2+/− compared with WT mice (P < 0.01), whereas Ang2 levels were reduced (P < 0.01), resulting in a more than twofold increase in the ratio of lung Ang1 to Ang2 levels (P < 0.05; Fig. 1 C). Under basal conditions, there was a modest but significant difference in RVSP between WT and Tie2+/− mice (P < 0.05), with 13% of the Tie2+/− mice demonstrating a RVSP measurement >37 mmHg (two standard deviations above mean RVSP of WT mice; χ², P < 0.05 compared with WT mice; Fig. 2 A); however, no significant change in baseline systemic systolic blood pressure (SBP; Fig. 2 B) or heart rate (unpublished data) was observed. A marked reduction in microvascular perfusion in the lungs of Tie2+/− compared with WT mice was observed after fluorescent microangiography (Fig. 2 C). Furthermore, this perfusion abnormality was more pronounced in mice with higher RVSPs. To further characterize their susceptibility to PAH, WT and Tie2+/− mice were subjected to 1 wk of hypoxic exposure (8–10% O2). Chronic hypoxia resulted in a significant increase in RVSP and right ventricle (RV) hypertrophy (P < 0.05 and 0.01, respectively, compared with normoxic controls), but there was no significant difference between the hypoxic WT and Tie2+/− mice observed (Fig. S1).

Effect of 5-HT or IL-6 on RVSP and RV hypertrophy
To determine the effect of well-known pulmonary hypertensive stimuli, RVSP (Fig. 3 A) and RV hypertrophy (Fig. 3 B) were assessed in WT and Tie2+/− mice after 1 wk of 5-HT infusion and 1 or 2 wk of IL-6 delivery. Treatment with 5-HT had no significant effect on RVSP in WT mice, although there was a trend (P < 0.1) toward an increase. However, 5-HT–treated Tie2-deficient mice exhibited a substantial increase in RVSP compared with their respective saline-treated controls (40 ± 4 vs. 25 ± 1 mmHg; P < 0.01). This increase was also significantly greater than that seen in WT mice exposed to 5-HT (27 ± 2 mmHg; P < 0.05). Although no significant effect on RVSP was observed in any group after 1 wk of IL-6 delivery, 2 wk of exposure to IL-6 induced a significant elevation in RVSP in Tie2+/− mice compared with IL-6–treated WT mice (31 ± 3 vs. 22 ± 1 mmHg; P < 0.05). A trend (P < 0.1) toward an increase in RVSP was also observed in Tie2+/− mice compared with their saline-treated controls. No significant change in RV hypertrophy was observed in either the WT or Tie2+/− mice during the short period of treatment with 5-HT. However, a significant increase in RV hypertrophy was observed in Tie2+/− compared with WT mice after 2 wk of exposure to IL-6 (P < 0.05).

Effect of 5-HT or IL-6 on Ang1 level and Tie2 activity
Western blot analysis was performed on lung homogenates from WT and Tie2+/− mice to determine whether treatment with 5-HT or IL-6 altered endogenous Ang1 levels (Fig. 4, A and B). After 1 wk of exposure to 5-HT or IL-6, Ang1 levels were significantly and similarly decreased in WT and Tie2+/− mice compared with their respective saline-treated
control groups (P < 0.05). To further establish the association between 5-HT and Ang1, human pulmonary artery smooth muscle cells (SMCs) were exposed for 24 h to 5-HT (10^{-8} - 10^{-5} M) or a combination of equal concentrations of IL-6 and a soluble IL-6R (sIL-6R; 10, 50, and 100 ng/ml), because past studies (Modur et al., 1997; Ammit et al., 2007) have demonstrated that the membrane-bound receptor may not be expressed in SMCs under in vitro conditions and that the soluble receptor is required to allow for IL-6 trans-signaling (Fig. S2). Ang1 secretion, as determined by ELISA performed on conditioned media, was reduced to ~60% in response to 5-HT or IL-6/sIL-6R (P < 0.01; Fig. 4, C and D).

To investigate the implications of these observations on in vivo Tie2 activity, Western blot analysis of phosphorylated Tie2 was performed on lung homogenates (Fig. 5, A and B). Although in WT mice no change in Tie2 receptor activation was observed after 5-HT infusion or IL-6 injections, Tie2^{+/-} mice displayed a significant decrease in lung Tie2 receptor activation compared with their saline-treated groups, in parallel to the decreases in Ang1 levels demonstrated in Fig. 4 (A and B) (P < 0.05). Because baseline levels of eNOS were significantly down-regulated in Tie2^{+/-} mice (Fig. 1 B), we examined eNOS protein expression in WT and Tie2^{+/-} mice after 5-HT infusion (Fig. S3). Interestingly, although there was no significant reduction in lung eNOS protein levels after 5-HT exposure, a trend toward a decrease (P < 0.1) was observed in the Tie2-deficient group.

Cell-death analysis
No terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling (TUNEL) staining or propidium iodide (PI) uptake was detected in saline-treated WT or Tie2^{+/-} mice (not depicted). In contrast, substantial TUNEL positivity was seen after 1 wk of exposure to 5-HT in Tie2-deficient but not in WT mice (7 vs. 0%; P < 0.01; Fig. 6 A). This increase in apoptosis was confirmed by in vivo perfusion of the pulmonary circulation with PI, which only stains the nuclei of nonviable cells. Again, only Tie2^{+/-} mice exposed to 5-HT demonstrated an increased uptake of PI (Fig. S4). Similarly, after 1 wk of exposure to IL-6, only Tie2-deficient mice
demonstrated TUNEL staining within peripheral regions of the lung (6%), whereas no staining was seen in WT mice (P < 0.01; Fig. 6 B).

**Effect of reduced Tie2 expression and 5-HT on pulmonary artery EC survival**
To further define the effect of decreased Tie2 receptor expression and signaling on EC survival in response to 5-HT, Tie2 was knocked down in human pulmonary artery ECs using specific silencing siRNA. Transfection with specific siRNA reduced Tie2 protein expression by ~50% by Western analysis, compared with control, scrambled siRNA–treated ECs (P < 0.01; Fig. 7 A). Furthermore, Tie2 silencing significantly enhanced EC apoptosis induced by 10 µM 5-HT cultured in low serum (0.2% fetal bovine serum) compared with cells treated with scrambled siRNA (P < 0.01; Fig. 7 B).

**Effect of 5-HT or IL-6 on pulmonary vascular remodeling**
Exposure to 5-HT for 1 wk did not result in any differences in the muscularization of pulmonary vessels <50 µm in diameter in either WT or Tie2-deficient mice (unpublished data). However, Tie2+/− mice exposed to 2 wk of IL-6 demonstrated a significant increase in muscularization compared with saline-treated Tie2+/− and IL-6-treated WT mice (P < 0.01 for both comparisons; Fig. 8, A and B). Preliminary studies demonstrated no overt phenotypic differences in extracellular matrix composition between WT and Tie2+/− mice after exposure to 5-HT or IL-6 (Fig. S5).

**Lack of PAH in Ang1 transgenic mice**
Protein expression of the human Ang1 transgene was detected in the mouse plasma of binary transgenic (BT) mice after induction by doxycycline withdrawal (Fig. S6). To define the effects of Ang1 overexpression on the development of PAH, RVSP and RV hypertrophy were determined in 11–12-wk-old Ang1 BT mice and non-BT (NBT) littermate controls that had been released from doxycycline suppression at 3 wk of age, and then received infusions of 5-HT or saline for 1 wk before end-study assessments. As presented in Fig. 9 A, there were no significant differences in RVSP between Ang1 BT and NBT mice receiving either saline or 5-HT infusions; if anything, RVSP tended to be reduced in BT mice, but this was not significant. As well, no differences in RV hypertrophy were observed between the groups after 1 wk of saline or 5-HT treatment (Fig. 9 B).

**Effect of caspase inhibition**
To further establish the role of EC apoptosis in the exaggerated pulmonary hypertensive response to 5-HT in vivo, we treated WT or Tie2-deficient animals with a pan-caspase inhibitor, Z-VAD. In WT mice, Z-VAD had no effect, whereas Tie2−/− mice receiving this treatment completely prevented the demonstrated TUNEL staining within peripheral regions of the lung (6%), whereas no staining was seen in WT mice (P < 0.01; Fig. 6 B).

**Effect of 5-HT or IL-6 on pulmonary vascular remodeling**
Exposure to 5-HT for 1 wk did not result in any differences in the muscularization of pulmonary vessels <50 µm in diameter in either WT or Tie2-deficient mice (unpublished data). However, Tie2+/− mice exposed to 2 wk of IL-6 demonstrated a significant increase in muscularization compared with saline-treated Tie2+/− and IL-6-treated WT mice (P < 0.01 for both comparisons; Fig. 8, A and B). Preliminary studies demonstrated no overt phenotypic differences in extracellular matrix composition between WT and Tie2+/− mice after exposure to 5-HT or IL-6 (Fig. S5).

**Lack of PAH in Ang1 transgenic mice**
Protein expression of the human Ang1 transgene was detected in the mouse plasma of binary transgenic (BT) mice after induction by doxycycline withdrawal (Fig. S6). To define the effects of Ang1 overexpression on the development of PAH, RVSP and RV hypertrophy were determined in 11–12-wk-old Ang1 BT mice and non-BT (NBT) littermate controls that had been released from doxycycline suppression at 3 wk of age, and then received infusions of 5-HT or saline for 1 wk before end-study assessments. As presented in Fig. 9 A, there were no significant differences in RVSP between Ang1 BT and NBT mice receiving either saline or 5-HT infusions; if anything, RVSP tended to be reduced in BT mice, but this was not significant. As well, no differences in RV hypertrophy were observed between the groups after 1 wk of saline or 5-HT treatment (Fig. 9 B).

**Effect of caspase inhibition**
To further establish the role of EC apoptosis in the exaggerated pulmonary hypertensive response to 5-HT in vivo, we treated WT or Tie2-deficient animals with a pan-caspase inhibitor, Z-VAD. In WT mice, Z-VAD had no effect, whereas Tie2−/− mice receiving this treatment completely prevented the demonstrated TUNEL staining within peripheral regions of the lung (6%), whereas no staining was seen in WT mice (P < 0.01; Fig. 6 B).

**Effect of 5-HT or IL-6 on pulmonary vascular remodeling**
Exposure to 5-HT for 1 wk did not result in any differences in the muscularization of pulmonary vessels <50 µm in diameter in either WT or Tie2-deficient mice (unpublished data). However, Tie2+/− mice exposed to 2 wk of IL-6 demonstrated a significant increase in muscularization compared with saline-treated Tie2+/− and IL-6-treated WT mice (P < 0.01 for both comparisons; Fig. 8, A and B). Preliminary studies demonstrated no overt phenotypic differences in extracellular matrix composition between WT and Tie2+/− mice after exposure to 5-HT or IL-6 (Fig. S5).

**Lack of PAH in Ang1 transgenic mice**
Protein expression of the human Ang1 transgene was detected in the mouse plasma of binary transgenic (BT) mice after induction by doxycycline withdrawal (Fig. S6). To define the effects of Ang1 overexpression on the development of PAH, RVSP and RV hypertrophy were determined in 11–12-wk-old Ang1 BT mice and non-BT (NBT) littermate controls that had been released from doxycycline suppression at 3 wk of age, and then received infusions of 5-HT or saline for 1 wk before end-study assessments. As presented in Fig. 9 A, there were no significant differences in RVSP between Ang1 BT and NBT mice receiving either saline or 5-HT infusions; if anything, RVSP tended to be reduced in BT mice, but this was not significant. As well, no differences in RV hypertrophy were observed between the groups after 1 wk of saline or 5-HT treatment (Fig. 9 B).

**Effect of caspase inhibition**
To further establish the role of EC apoptosis in the exaggerated pulmonary hypertensive response to 5-HT in vivo, we treated WT or Tie2-deficient animals with a pan-caspase inhibitor, Z-VAD. In WT mice, Z-VAD had no effect, whereas Tie2−/− mice receiving this treatment completely prevented the demonstrated TUNEL staining within peripheral regions of the lung (6%), whereas no staining was seen in WT mice (P < 0.01; Fig. 6 B).
The distal pulmonary arteriolar bed is unique in that it consists of little more than an endothelial tube with scant matrix and few, if any, supporting mural cells. Thus, the ECs of the precapillary arterioles may be particularly vulnerable to injurious stimuli, and thereby more dependent on survival signaling, such as that afforded by Ang1 and vascular endothelial growth factor, to maintain lung vascular homeostasis. This is consistent with previous observations that inhibiting vascular endothelial growth factor signaling can potentiate experimental PAH (Taraseviciene-Stewart et al., 2001), whereas overexpression of angiogenic factors can be protective (Janssens et al., 1996; Campbell et al., 2001; Zhao et al., 2003; Kugathasan et al., 2005; Zhao et al., 2005). Moreover, we hypothesize that the functional consequences of even low levels of EC apoptosis may be particularly important for this region, because there is a finite possibility that this could disrupt the functional continuity between the arteriolar and capillary circulations, effectively excluding an “arteriolar-capillary unit” from the efficient “low pressure” pulmonary circulation. If this occurs repeatedly over time throughout the lung microvasculature, this would result in progressive increases in pulmonary vascular resistance.

Tie2 is an endothelial-selective receptor tyrosine kinase that is essential for vascular growth and remodeling. A null mutation of \textit{Tie2} results in embryonic lethality at E9.5–12.5 with marked vascular abnormalities, including reduced vascular exaggeration in RVSP induced by 5-HT (P < 0.01; Fig. 10 A). In addition, no significant change in RV hypertrophy was present at 1 wk (Fig. 10 B). Furthermore, no TUNEL-positive cells were detected in the lungs of \textit{Tie} \textsuperscript{2+/-} mice receiving both 5-HT and Z-VAD (not depicted).

**DISCUSSION**

In this study, we examined whether alterations in Tie2 activity would protect or predispose to the development of PAH using loss- and gain-of-function transgenic models. Ang1 overexpression by itself did not induce PAH, and \textit{Tie2} haploinsufficiency resulted in spontaneous increases in RVSP in a small proportion of mice under basal conditions. Moreover chronic treatment of Tie2-deficient mice with 5-HT or IL-6 unmasked significant elevation in pulmonary arterial pressures compared with WT animals. These interventions also reduced lung Ang1 levels and Tie2 activity, and induced EC apoptosis both in vivo and in vitro, but only in the context of Tie2 deficiency. As well, inhibition of apoptosis with Z-VAD completely prevented the pulmonary hypertensive response to 5-HT in Tie2 \textsuperscript{2+/+} mice. These data strongly suggest that the Ang1–Tie2 pathway protects against PAH, in large part by promoting EC survival under conditions of serotonergic or inflammatory stress, both of which have been strongly implicated in the pathogenesis of this disease.

![Figure 3. Effect of 5-HT or IL-6 on RVSP and RV hypertrophy.](image)

(A) Increased RVSP in \textit{Tie2} \textsuperscript{2-/-} mice exposed to 5 nmol/h 5-HT for 1 wk compared with WT mice and compared with saline-treated \textit{Tie2} \textsuperscript{2+/-} mice (n = 12–15 mice per group). Increased RVSP in \textit{Tie2} \textsuperscript{2+/+} mice exposed to 200 ng/kg/d IL-6 for 2 wk compared with WT mice (n = 9–13 mice per group). (B) No change in RV hypertrophy, assessed by evaluating the mass ratio of the RV to the left ventricle plus septum (LV+S), in WT or \textit{Tie2} \textsuperscript{2+/-} mice exposed to 5 nmol/h 5-HT for 1 wk compared with saline-treated groups (n = 12–15 mice per group). Increased RV hypertrophy in \textit{Tie2} \textsuperscript{2+/-} mice exposed to IL-6 for 2 wk compared with WT mice (n = 9–13 mice per group). Results are from three independent experiments. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01 as indicated.
contribute to EC dysfunction and loss in this model. Thus, we hypothesized that Tie2 deficiency would exaggerate pulmonary vascular response to relevant environmental triggers of PAH by predisposing to EC apoptosis and microvascular degeneration.

Despite the evidence supporting a key role for the Ang1–Tie2 pathway in maintaining vascular homeostasis, it has previously been suggested that Ang1 may be causally related to the development of PAH (Thistlethwaite et al., 2001; Du et al., 2003). This was based on the observation that Ang1 complexity, increased EC apoptosis, and an absence in mural cell recruitment (Davis et al., 1996). Furthermore, Ang1 is highly expressed by SMCs and pericytes in the postnatal vasculature, and promotes vascular stabilization and maintenance of EC quiescence (Maisonpierre et al., 1997). Of interest, the lung exhibits some of the highest levels of basal Ang1 expression of any organ in the body (Wong et al., 1997). In addition, Tie2-deficient mice exhibited a marked down-regulation of lung eNOS protein levels, and any reduction in the release of the vascular protective and EC survival factor, NO, could contribute to EC dysfunction and loss in this model. Thus, we hypothesized that Tie2 deficiency would exaggerate pulmonary vascular response to relevant environmental triggers of PAH by predisposing to EC apoptosis and microvascular degeneration.

Figure 4. Effect of 5-HT or IL-6 on Ang1 protein levels in vivo and in vitro. (A) Decreased lung Ang1 protein levels in WT and Tie2+/− mice after exposure to 5-HT (A; n = 5 mice per group) or IL-6 (B; n = 5 mice per group) for 1 wk. (C and D) Decreased Ang1 protein secretion measured by ELISA in pulmonary artery SMCs serum starved overnight and stimulated with 10−8–10−5 M 5-HT (C; n = 4 per group) or equal concentrations of a combination of IL-6 and sIL-6R (10, 50, and 100 ng/ml; D; n = 4 per group) for 24 h. Results in A and B are from two independent experiments; results in C and D are from four independent experiments. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01 versus saline (in vivo) or control (in vitro).
was robustly expressed in lung samples from associated PAH patients, and was strongly correlated with increases in pulmonary vascular resistance, whereas Ang1 protein and Tie2 activity were nearly undetectable in control human lung samples (Thistlethwaite et al., 2001; Du et al., 2003). However, these findings are in conflict with other reports showing that Ang1 is highly expressed in normal human and rodent lungs (Wong et al., 1997; Witzenbichler et al., 1998; Abdulmalek et al., 2001; Kugathasan et al., 2005), and an up-regulation of Ang1 in PAH has not been confirmed by other groups (Kugathasan et al., 2005; Dewachter et al., 2006). It is possible that the near-complete absence of Ang1 mRNA and protein expression in control lung samples in the initial Thistlethwaite report (Thistlethwaite et al., 2001) was related to their use of lobectomy samples from routine surgeries, which are often subjected to variability in processing speed and duration to storage before analysis. Indeed, we have found that the levels of Ang1 mRNA and protein fall off precipitously even after a 15-min delay in the processing of lung samples (unpublished data).

The Thistlethwaite group also demonstrated that increasing Tie2 activity by Ang1 gene transfer resulted in medial hyperplasia of pulmonary arterioles, vascular obstruction, and PAH (Sullivan et al., 2003; Chu et al., 2004), whereas inhibition of this signaling pathway via gene transfer of the extracellular domain of Tie2 (soluble Tie2) was protective (Kido et al., 2005). However, patients with an activating mutation of Tie2 show no evidence of PAH but rather develop large venous malformations, which exhibit either normal muscularization or vascular walls that are totally devoid of medial SMCs (Vikkula et al., 1996). Moreover, using a conditional transgenic Ang1 overexpression strategy to avoid the confounding effects of viral vectors, we found no evidence of an increase in RVSP or RV remodeling even 9 wk after induction of Ang1 gene expression. Furthermore, BT mice harboring both the tetracycline trans-activator and the Ang1 transgenes showed no evidence of enhanced susceptibility to PAH in response to serotonergic stress, and if anything, this was blunted. These findings are consistent with previous studies in which nonviral Ang1 gene transfer prevented PAH in rats in both the monocrotaline and hypoxia models (Zhao et al., 2003; Kugathasan et al., 2005).

The reasons for the marked discrepancies between our findings and those of the Thistlethwaite group are not clear; however, this may relate to differences in the experimental approaches. For example, their studies used viral vectors for gene transfer that can induce inflammation. It is also possible that differences in the overall magnitude of transgene expression (i.e., “dose”) or spatial distribution may have contributed to these divergent results, and that higher levels of local Ang1 expression within the lung microvasculature could induce nonphysiological effects, such as increased muscularization and arterial remodeling. Finally, surgical manipulation such as the clamping of the pulmonary veins that was used to enhance the levels of transgene expression in the lung in these studies (Sullivan et al., 2003; Kido et al., 2005) could have damaged these delicate venous structures. It is well established in the electrophysiology literature that injury to pulmonary veins is an important cause of pulmonary hypertension (Robbins et al., 1998; Tsao and Chen, 2002; Yang et al., 2007). In our study, the use of a conditional, targeted transgenic model may have avoided some of these confounding effects.

Of note, we found an increase in basal levels of Ang1 in Tie2+/− mice compared with WT mice, which was associated with decreased Ang2 expression. This resulted in a marked increase in the ratio of the Tie2 agonist over the antagonist, which could serve to enhance activation of the remaining receptors, possibly in compensation for the effects of Tie2 haploinsufficiency. Although overt PAH was not evident in most Tie2-deficient mice, abnormalities in distal microcirculatory perfusion were revealed by fluorescent microangiography, which were similar to those observed in a dominant-negative

Figure 5. Effect of 5-HT or IL-6 on lung Tie2 activity. (A and B) Decreased activation of Tie2, assessed by normalizing levels of phosphorylated Tie2 to total Tie2, in Tie2−/− mice treated with 5-HT (A; n = 4 mice per group) or IL-6 (B; n = 4 mice per group) for 1 wk compared with saline-treated Tie2+/− mice. No change in Tie2 activation was observed in WT mice. Results in A and B are from two independent experiments. Data are presented as means ± SEM.* P < 0.05 versus respective saline Tie2−/− mice.
BMPR2 transgenic mouse model (West et al., 2008) and consistent with subthreshold effects on vascular structure and function. In the present study, exposure to 5-HT or IL-6 alone did not induce a significant elevation in RVSP in WT mice; similarly, Tie2 deficiency by itself resulted in only a minor effect. However, the combination of these genetic and environmental influences appeared to have “synergistic” effects resulting in the initiation of pulmonary apoptosis and the development of significant PAH. This is consistent with the “second-hit” hypothesis for the pathogenesis of this disease, in which the response to an environmental or endogenous trigger is enhanced by the presence of a sensitizing genetic abnormality (Newman et al., 2004; Song et al., 2005; Long et al., 2006; Song et al., 2008). In a manner analogous to the present findings, exposure to serotonergic (Long et al., 2006) or inflammatory stressors (Song et al., 2005) also produced an enhanced pulmonary hypertensive response in BMPR2+/− mice. Interestingly, as in Tie2-deficient mice, exposure to

![Figure 6. Effect of 5-HT or IL-6 on lung apoptosis. (A and B) Increased TUNEL staining in Tie2−/− compared with WT mice after exposure to 5-HT (A; n = 4 mice per group) or IL-6 (B; n = 4 mice per group) for 1 wk. TUNEL staining on 5-µm-thick paraffin-embedded lung sections from (a) WT and (c) Tie2−/− mice. Merged image of TUNEL and nuclear stainings (TO-PRO-3) of (b) WT and (d) Tie2−/− mice (arrows indicate TUNEL-positive cells). (e) Magnified view of TUNEL-positive cells (arrows) and (f) the percentage of TUNEL-positive cells. Results in A and B are from two independent experiments. Data are presented as means ± SEM. **, P < 0.01 versus WT. Bars: (a–d) 50 µm; (d, inset) 25 µm; (e) 12.5 µm.](image)
Similarly, 5-HT has been strongly implicated in PAH, with idiopathic PAH patients demonstrating elevated circulating levels of 5-HT (Hervé et al., 1995). In experimental models, administration of dexfenfluramine (Dempse et al., 2008), a 5-HTT substrate that also elevates extracellular levels of 5-HT (Rothman et al., 1999), has been shown to induce PAH in mice. In addition, several genetic and pharmacological models to either increase or decrease the activity of 5-HT receptors or the transporter have further highlighted the role of 5-HT in PAH (MacLean et al., 1996; Morecroft et al., 1999; Eddahibi et al., 2000; Keegan et al., 2001; Hironaka et al., 2003; Marcos et al., 2003; MacLean et al., 2004; Guignabert et al., 2005; Long et al., 2006; Morecroft et al., 2007), in part through its direct stimulatory effects on pulmonary arterial SMCs. However, the effects of 5-HT on EC growth and survival have not been as extensively studied. Lee et al. (1994) have reported that although 5-HT stimulated DNA synthesis in bovine pulmonary artery SMCs, this effect was not seen in pulmonary artery ECs. Similarly, we found no effects of 5-HT on EC growth and survival under basal conditions, but substantial EC apoptosis was demonstrated in response to 5-HT after siRNA-induced Tie2 gene silencing. Thus, 5-HT may have differential effects on pulmonary vascular cells; although in SMCs it promotes proliferation, in ECs it may induce injury and apoptosis. This is analogous to the effects of BMPR2 deficiency or gene silencing, which also results in dysregulated SMC growth but unmasks increased EC apoptosis (Teichert-Kuliszewska et al., 2006). Moreover, we were able to establish that apoptosis was an important mechanism in the exaggerated PAH seen in Tie2-deficient animals in response to serotonergic stress, because this could be abrogated with the pan-caspase inhibitor Z-VAD. This is consistent with EC apoptosis playing a central role in the pathogenesis of PAH, possibly by chronic hypoxia did not result in greater PAH in BMPR2+/− compared with WT mice (Long et al., 2006).

Lung Ang1 protein levels were reduced by treatment with serotonergic or inflammatory mediators in both WT and Tie2+/− mice. This was associated with decreased Tie2 activation that was more pronounced in Tie2+/− compared with WT mice. Moreover, evidence of apoptosis was seen in the peripheral lungs in Tie2+/− mice exposed to 5-HT or IL-6 but not in WT littermates. Because Ang1 is primarily produced by periendothelial support cells, we examined the effect of these agents on Ang1 secretion by cultured pulmonary artery SMCs. In parallel to our findings in vivo, we observed a dose-dependent reduction in Ang1 secretion in response to both 5-HT and IL-6. Thus, in a Tie2-deficient genetic background, these mediators could act to interfere with an important compensatory mechanism and exacerbate the effect of haploinsufficiency on the activity of the Tie2 pathway.

5-HT and IL-6 may also exert direct effects on EC inflammation and survival. Both IL-6 and 5-HT are known to be elevated in the serum of patients with PAH (Hervé et al., 1995; Humbert et al., 1995; Itoh et al., 2006), and they have been shown to induce PAH in rats and mice (Eddahibi et al., 1997; Golembeski et al., 2005; Steiner et al., 2009). Increased circulating IL-6 has also been shown to be associated with increased evidence of EC apoptosis (Chirinos et al., 2005). As well, this mediator has been strongly implicated in EC activation and proinflammatory signaling in the context of PAH (Yoshio et al., 1997; Lesprit et al., 1998; Nishimaki et al., 1999). Recently, it has been suggested that increased susceptibility to PAH induced by BMPR2 mutations may be attributable in part to the loss of inhibitory effects of BMPs on IL-6 (Hagen et al., 2007), resulting in a positive feedback loop of inflammatory cytokine signaling.

Similarly, 5-HT has been strongly implicated in PAH, with idiopathic PAH patients demonstrating elevated circulating levels of 5-HT (Hervé et al., 1995). In experimental models, administration of dexfenfluramine (Dempse et al., 2008), a 5-HTT substrate that also elevates extracellular levels of 5-HT (Rothman et al., 1999), has been shown to induce PAH in mice. In addition, several genetic and pharmacological models to either increase or decrease the activity of 5-HT receptors or the transporter have further highlighted the role of 5-HT in PAH (MacLean et al., 1996; Morecroft et al., 1999; Eddahibi et al., 2000; Keegan et al., 2001; Hironaka et al., 2003; Marcos et al., 2003; MacLean et al., 2004; Guignabert et al., 2005; Long et al., 2006; Morecroft et al., 2007), in part through its direct stimulatory effects on pulmonary arterial SMCs. However, the effects of 5-HT on EC growth and survival have not been as extensively studied. Lee et al. (1994) have reported that although 5-HT stimulated DNA synthesis in bovine pulmonary artery SMCs, this effect was not seen in pulmonary artery ECs. Similarly, we found no effects of 5-HT on EC growth and survival under basal conditions, but substantial EC apoptosis was demonstrated in response to 5-HT after siRNA-induced Tie2 gene silencing. Thus, 5-HT may have differential effects on pulmonary vascular cells; although in SMCs it promotes proliferation, in ECs it may induce injury and apoptosis. This is analogous to the effects of BMPR2 deficiency or gene silencing, which also results in dysregulated SMC growth but unmasks increased EC apoptosis (Teichert-Kuliszewska et al., 2006). Moreover, we were able to establish that apoptosis was an important mechanism in the exaggerated PAH seen in Tie2-deficient animals in response to serotonergic stress, because this could be abrogated with the pan-caspase inhibitor Z-VAD. This is consistent with EC apoptosis playing a central role in the pathogenesis of PAH, possibly by...
leading directly to the degeneration and loss of function of distal precapillary arterioles. More importantly, these findings also emphasize the protective role of the Tie2 signaling pathway in preventing apoptosis and protecting against the development of PAH. Thus, interventions that inhibit the apoptotic cascade may be therapeutically useful in preventing the progression of PAH and need to be investigated.

In this study, we have shown that Tie2 haploinsufficiency increased the susceptibility of transgenic mice to PAH, likely by sensitizing ECs to apoptosis in response to a second hit, such as exposure to 5-HT or a proinflammatory mediator.

**MATERIALS AND METHODS**

**Animals**

All animal procedures were approved by the Animal Care Committee of St. Michael’s Hospital. Breeding pairs to generate Tie2<sup>+/−</sup> mice and Ang1<sup>BT</sup> mice were provided by D.J. Dumont (University of Toronto, Toronto, Ontario).

Both agents decreased Ang1 secretion, which in the Tie2-deficient background likely resulted in reduction in Tie2 activity below a critical threshold. In contrast to some previous reports, overexpression of Ang1 had no deleterious effects on pulmonary hemodynamics or vascular remodeling, a finding consistent with the now well-established role of Tie2 activity in maintaining vascular homeostasis. Collectively, these findings suggest that rather than promoting vascular remodeling and PAH, pulmonary Ang1 may be protective by supporting the basal activation of endothelial Tie2. Thus, these data may have important clinical implications by suggesting that therapeutic strategies based on inhibiting Tie2 activity may be harmful, whereas Ang1 and other Tie2 agonists may be useful in the treatment of this serious disorder.

**Figure 8.** Effect of IL-6 on pulmonary arterial medial thickening. (A) Immunofluorescent images of vessels stained with α-smooth muscle actin from 2 wk of (a) saline-treated WT, (b) saline-treated Tie2<sup>+/−</sup>, (c) IL-6-treated WT, and (d) IL-6-treated Tie2<sup>+/−</sup> mice (n = 4 mice per group). (B) Increased percentage of wall thickness of pulmonary arteries <50 µm in external diameter in Tie2<sup>+/−</sup> mice exposed to IL-6 for 2 wk compared with WT mice and compared with saline-treated Tie2<sup>+/−</sup> mice (n = 4 mice per group). Results are from two independent experiments. Data are presented as means ± SEM. **, P < 0.01 as indicated. Bars, 25 µm.

**Figure 9.** Effect of Ang1 overexpression on RVSP and RV hypertrophy. (A and B) No effect on RVSP (A; n = 6–10 mice per group) or RV hypertrophy (B; n = 6–10 mice per group) in NBT and Ang1 BT mice treated with 5 nmol/h 5-HT for 1 wk. Mice were released from doxycycline suppression at 3 wk of age and exposed to 5-HT for 1 wk at 11–12 wk of age. Results are from three independent experiments. Data are presented as means ± SEM.

**Figure 10.** Effect of Z-VAD on 5-HT–treated WT and Tie2<sup>+/−</sup> mice. (A) Significant decrease in RVSP in 5-HT–treated Tie2<sup>+/−</sup> mice after simultaneous treatment with 3 mg/kg Z-VAD for 1 wk (n = 3–5 mice per group). (B) No significant change in RV hypertrophy was observed (n = 3–5 mice per group). Results are from two independent experiments. Data are presented as means ± SEM. **, P < 0.01 versus 5-HT + DMSO Tie2<sup>+/−</sup> mice.
Groups of three mice were placed in sealed anaesthetized and the pulmonary vessels were flushed through the RV. This technique was adapted from Dutly et al. (2006). In brief, mice were anesthetized mice by inserting the 1.4F Millar catheter into the RV. RV hypertension at 72°C for 10 min was performed, and the amplified DNA was recovered from each of three mice from each experimental group were analyzed using TUNEL assay kit (Promega) according to manufacturer’s instructions. Nuclear counterstaining was performed using TO-PRO-3 (200 mg/kg ketamine:10 mg/kg xylazine) and allowed to circulate for 15 min before the mice were euthanized. The left atrium was transected, and the systemic and pulmonary circulations were flushed with PBS. Lungs were fixed in optimum cutting temperature and stored at −80°C overnight. The next day, 60-µm-thick cross sections of the left lobe of the lungs were cryosectioned for confocal microscopy. Cells that did not exclude the PI were considered to be nonviable.

**TUNEL**

Apoptotic cells were detected in 5-µm-thick paraffin-embedded sections using a fluorescent TUNEL assay kit (Promega) according to manufacturer’s instructions. Nuclear counterstaining was performed using TO-PRO-3 (1:2,500; Invitrogen), and sections were examined by confocal microscopy (40× magnification; Radiance 2100) and images were acquired using LaserSharp software (both from Bio-Rad Laboratories). The number of TUNEL-positive nuclei was determined by examining four randomly selected microscopic fields from each of four to five mice from each experimental group. The percentage of TUNEL positivity was calculated as follows: (number of TUNEL-positive nuclei)/(total number of nuclei) × 100%.

**Western immunoblotting**

Protein was extracted from the lungs of WT and Tie2+/− mice and subjected to immunoblotting. Membranes were incubated overnight at 4°C with rabbit eNOS antibody (1:1,000; Cell Signaling Technology), rabbit Phospho-Tie2 antibody (1:1,000; Cell Signaling Technology), rabbit Tie2 antibody (1:1,000; Santa Cruz Biotechnology, Inc.), rabbit Ang1 antibody (1:1,000; Abcam), or goat Ang2 antibody (1:500; Santa Cruz Biotechnology, Inc.), and equivalent protein loading was demonstrated using mouse β-actin antibody (1:5,000; Sigma-Aldrich).

**Muscularization analysis**

5-µm-thick paraffin-embedded sections were stained with a Cy3-conjugated monoclonal α-smooth muscle actin antibody (1:200; Sigma-Aldrich), and nuclei were counterstained using TO-PRO-3 (1:2,500). Sections were examined by confocal microscopy (80× magnification; Radiance 2100) and images were acquired using LaserSharp software. The percentage of wall thickness was determined using the methodology by Beppu et al. (2004) and was as follows: % wall thickness = (WT1 + WT2)/(external diameter of vessel) × 100%, where WT1 and WT2 refer to wall thicknesses measured at two points diametrically opposite to each other. For each vessel, the percentage of wall thickness was calculated as the average determined from four regions of measurement.

**Movat pentachrome staining**

The Movat pentachrome staining was performed on 5-µm-thick paraffin-embedded sections to demonstrate extracellular matrix components such as fibrin, collagen, elastin, and proteoglycans/glycosaminoglycans. Vessels from four to five randomly selected microscopic fields (10× magnification) from each of three mice from each experimental group were analyzed using.
a bright-field upright light microscope (model E800) equipped with a digital camera (DXM 1200), and images were acquired using Act-1 software (all from Nikon).

**Human pulmonary artery SMC culture**

Human pulmonary artery SMCs (Lonza, Ltd.) at 70–80% confluency were serum starved in basal medium with 0.1% BSA for 24 h and exposed to 5-HT (Sigma-Aldrich) at concentrations of $10^{-3}$–$10^{-1} \text{ M}$ for 24 h. In a separate experiment, serum-starved cells were exposed to a combination of human IL-6 and human IL-6R (IL-6 + sIL-6R; Sigma-Aldrich), each at concentrations of 10, 50, and 100 ng/ml for 24 h. At the end of the experiment, supernatants were collected for ELISA and cells were harvested for protein quantification.

**Detecting membrane-bound IL-6R**

Protein was harvested from human pulmonary artery SMCs and human endothelial progenitor cells were cultured for 7 d (positive control). Membranes were incubated overnight at 4°C with rabbit IL-6R antibody (1:500; Santa Cruz Biotechnology, Inc.).

**ELISA**

Human Ang1 levels from human pulmonary artery SMC supernatants were measured according to the manufacturer’s instructions (R&D Systems).

**Human pulmonary artery EC Tie2 siRNA**

siRNA-mediated inhibition of Tie2 gene expression (Santa Cruz Biotechnology, Inc.) in human pulmonary artery ECs (Lonza, Ltd.) was performed according to the manufacturer’s instructions, and control cells were subjected to scrambled siRNA transfection. After siRNA treatment, cells were exposed to $10^{-5}$ M 5-HT in basal medium with 0.2% FBS for 24 h. At the end of this treatment, cells were labeled with annexin V and PI (Annexin-V-FLUOS staining kit; Roche) and analyzed by flow cytometry to determine the percentage of cell death.

**Statistical analysis**

All data are presented as means ± SEM. For in vivo experiments, means of two groups were compared using either an unpaired t-test, or the nonparametric Mann-Whitney U test. Differences among multiple means were determined by analysis of variance (ANOVA), followed by the Student-Newman-Keuls post-hoc analysis, or the nonparametric Kruskal-Wallis test followed by the Dunn’s post-hoc analysis. For in vitro experiments, repeated-measures ANOVA was used when appropriate, followed by the Dunnett’s post-hoc analysis.

**Online supplemental material**

Fig. S1 demonstrates that hypoxia did not elicit more significant PAH in Tie2−/− compared with WT mice. Fig. S2 confirms that the membrane-bound IL-6R is not expressed in pulmonary arterial SMCs in culture. Fig. S3 demonstrates that lung eNOS protein levels are not significantly altered in WT or Tie2−/− mice after exposure to 5-HT, although a trend toward a decrease in eNOS protein levels was present in the Tie2−/− mice. Fig. S4 illustrates the presence of nonviable cells in the lungs of 5-HT–treated Tie2−/− mice via in vivo PI uptake. Fig. S5 demonstrates the absence of any overt phenotypic differences after Movat pentachrome staining between WT and Tie2−/− mice treated with 5-HT or IL-6. Fig. S6 confirms the expression of human Ang1 protein in the plasma of Ang1 BT mice. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20090389/DC1.

We thank Ms. C. Wang, Mr. M. Robb, Dr. M. Golam Kabir, and Dr. R.N.N. Han for technical assistance, and Ms. L. Morikawa for the Movat pentachrome staining. We also thank Mr. P.F.H. Lai, Dr. M.E. Ward, and Dr. K. Teichert-Kuliszewska for helpful discussions.

This work was supported by grants to D.J. Stewart from the Canadian Institutes of Health Research (MOP-57726 and MOP-82791), and L. Kugathasan holds a Doctoral Canada Graduate Scholarship from the Natural Sciences and Engineering Research Council of Canada.

The authors have no conflicting financial interests.

Submitted: 19 February 2009
Accepted: 19 August 2009

**REFERENCES**


SUPPLEMENTAL MATERIAL

Kugathasan et al., http://www.jem.org/cgi/content/full/jem.20090389/DC1

Figure S1. Effect of hypoxia on RVSP and RV hypertrophy. (A and B) Increased RVSP (A; n = 7–9 mice per group) and RV hypertrophy (B; n = 7–9 mice per group) in WT and Tie2+/− mice after 1 wk of hypoxic exposure compared with respective normoxic groups. Results are from three independent experiments. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01 as indicated.

Figure S2. Detection of IL-6R in pulmonary arterial SMCs. Lack of expression of membrane-bound IL-6R in cultured human pulmonary artery SMCs (n = 2). Human endothelial progenitor cells (EPC) cultured for 7 d were used as a positive control (n = 2). Results are from one experiment.
**Figure S3.** Effect of 5-HT on lung eNOS protein levels. No significant change in eNOS protein levels was observed in WT and Tie2+/− mice after exposure to 5 nmol/h 5-HT, although a trend toward a decrease in Tie2+/− mice was present (P < 0.1; n = 5 mice per group). Results are from two independent experiments.

**Figure S4.** In vivo apoptosis analysis. Increased in vivo PI uptake in Tie2−/− compared with WT mice treated with 5-HT for 1 wk (n = 4 mice per group). Representative photomicrographs are from one experiment. Bars, 50 μm.
Figure S5. Movat pentachrome staining. No overt phenotypic differences were observed between WT and Tie2+/− mice after exposure to 5-HT (n = 3 mice per group) or IL-6 (n = 3 mice per group). Arrows (left panels in each column) indicate vessels magnified and presented (right panels in each column). Representative photomicrographs are from one experiment. Bars: (left) 200 μm; (right) 50 μm.

Figure S6. Detection of plasma human Ang1 expression. Presence of human Ang1 levels in the plasma of Ang1 BT mice after 9 wk of transgene overexpression, whereas NBT mice demonstrated no detectable plasma human Ang1 levels (n = 3 mice per group). Results are from one experiment. Data are presented as means ± SEM. **, P < 0.01 versus NBT mice.